Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Rheumatoid arthritis affects individuals commonly during the most productive years of adulthood. Poor response rates and high costs associated with treatment mandate the search for new therapies. Here we show that targeting a specific G-protein coupled receptor promotes senescence in synovial fibroblasts, enabling amelioration of joint inflammation. Following activation of the melanocortin type 1 receptor (MC1), synovial fibroblasts acquire a senescence phenotype characterized by arrested proliferation, metabolic re-programming and marked gene alteration resembling the remodeling phase of wound healing, with increased matrix metalloproteinase expression and reduced collagen production. This biological response is attained by selective agonism of MC1, not shared by non-selective ligands, and dependent on downstream ERK1/2 phosphorylation. In vivo, activation of MC1 leads to anti-arthritic effects associated with induction of senescence in the synovial tissue and cartilage protection. Altogether, selective activation of MC1 is a viable strategy to induce cellular senescence, affording a distinct way to control joint inflammation and arthritis.

Original publication

DOI

10.1038/s41467-020-14421-x

Type

Journal article

Journal

Nat Commun

Publication Date

06/02/2020

Volume

11

Keywords

Animals, Arthritis, Experimental, Arthritis, Rheumatoid, Cells, Cultured, Cellular Senescence, Fibroblasts, Genetic Variation, Humans, Imidazoles, Male, Metabolic Networks and Pathways, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptor, Melanocortin, Type 1, Receptors, Notch, Synovial Membrane, alpha-MSH